NATICK, Massachusetts and NICE, France, June 18, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.
The sub-analysis demonstrated that both men and women experienced significant benefit from cardiac resynchronization therapy. However, women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men. Additional analysis demonstrated that women with asymptomatic or mild heart failure experienced a 72 percent reduction in all-cause mortality.
"There are a number of factors that may explain why women experienced a
greater benefit than men," said Arthur Moss, M.D., Professor of Medicine at
the University of Rochester Medical Center and Principal Investigator of the
MADIT-CRT trial. "CRT-D therapy is designed to improve the heart's overall
pumping ability and women are more likely than men to have non-ischemic heart
disease, which typically affects the entire heart rather than a single region
and can lead to reduced pumping strength, abnormal heart rhythms and
disturbances in the heart's electrical system. Men are more likely to have
ischemic heart disease, also known as coronary ar
|SOURCE Boston Scientific Corporation|
Copyright©2010 PR Newswire.
All rights reserved